目的：比较托特罗定和奥昔布宁在小儿原发性膀胱过度活动症（OAB）的疗效和安全性。方法：共204例确诊为OAB的患儿随机分为安慰剂组68例、托特罗定组68例和奥昔布宁组68例，疗程2周后评估疗效及安全性。结果：安慰剂组总有效率为25%，托特罗定组总有效率达89%，奥昔布宁组有效率达92%，托特罗定组和奥昔布宁组疗效明显高于安慰剂组（P<0.05），托特罗定组和奥昔布宁组疗效相似。托特罗定组不良反应发生率为28%，而奥昔布宁组不良反应发生率为57%,托特罗定组不良反应发生率明显低于奥昔布宁组（P<0.05）。结论：在小儿OAB的药物治疗中，托特罗定和奥昔布宁疗效相似，但托特罗定具有更好的安全性。
Abstract
OBJECTIVE: To compare the efficacy and safety of tolterodine and oxybutynin in the treatment of idiopathic overactive bladder in children. METHODS: A total of 204 children with idiopathic overactive bladder were randomly divided into three groups (n=68 each): placebo, tolterodine-treated and oxybutynin-treated. The efficacy and safety were evaluated two weeks after treatment. RESULTS: The effective rate was 25% in the placebo group, 89% in the tolterodine-treated group, and 92% in the oxybutynin-treated group. The effective rate in the two treatment groups was significantly higher than that in the placebo group (P<0.05). There was a similar efficacy between the two treatment groups. The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0.05). CONCLUSIONS: Tolterodine has a similar efficacy to oxybutynin in the treatment of idiopathic overactive bladder in children, with better safety in pharmacotherapy.
关键词
托特罗定 /
奥昔布宁 /
膀胱过度活动症 /
儿童
Key words
Tolterodine /
Oxybutynin /
Overactive bladder /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］Nevéus T, Von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children′s Continence Society［J］. J Urol, 2006, 176(1): 314-324.
［2］Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study［J］. Int J Urol, 2006, 13(1): 36-41.
［3］Hommaa Y, Yoshidab M, Sekic N, Yokoyamad O, Kakizakie H, Gotohf M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score［J］. Urology, 2006, 68(2): 318-323.
［4］唐达星,孙革. 托特罗定与颠茄合剂治疗儿童逼尿肌过度活跃症疗效比较［J］. 中华小儿外科杂志,2007,28(7):389-390.
［5］Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder［J］. Int Urogynecol J Pelvic Floor Dysfunct,1999,10(5): 283-289.
［6］吴士良，崔一民，杨勇，段继宏，那彦群，徐祗顺，等. 酒石酸托特罗定与奥昔布宁双盲双模拟随机对照治疗膀胱过度活动症多中心临床研究［J］. 中国临床药理学杂志,2001,17(5): 337-340.
［7］Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine--a new bladder-selective antimuscarinic agent［J］. Eur J Pharmacol,1997,327(2-3): 195-207.
［8］Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoorne J, Vande Walle J. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder［J］. Eur Urol,2004, 45(2): 240-244.
［9］Hjalmas K, Hellstrom AL, Mogren K, Lackgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine［J］. BJU Int, 2001, 87(6): 569-574.
［10］Nijman R, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials［J］. J Urol, 2005, 173(4): 1334-1339.
［11］Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability［J］. Int J Urol, 2006, 13(2): 105-108.
［12］Bolduc S, Upadhyay J, Payton J, Bagli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure［J］. BJU Int, 2003, 91(4): 398-401.
［13］Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for Therapy Resistant Overactive Bladder［J］. J Urol, 2009, 182(4): 2040-2044.
PDF(887 KB)
